Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI. et al, (2021), Br J Cancer, 125, 520 - 527
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA. et al, (2021), Leukemia, 35, 2424 - 2430
Sequencing therapies in Hodgkin lymphoma.
Phillips EH. et al, (2021), Lancet Haematol, 8, e537 - e539
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP. et al, (2021), Blood Adv, 5, 2852 - 2862
The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.
Mughal TI. et al, (2021), Haematologica, 106, 1787 - 1793
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.
Harrington K. et al, (2021), CANCER RESEARCH, 81
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N. et al, (2021), Adv Ther, 38, 3789 - 3802
The clinical and molecular significance associated with STING signaling in breast cancer.
Parkes EE. et al, (2021), NPJ Breast Cancer, 7
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
Kazmi F. et al, (2021), Clin Cancer Res, 27, 3028 - 3038
A qualitative exploration of the barriers to and facilitators of clozapine monitoring in a secure psychiatric setting.
Blagden S. et al, (2021), BJPsych Bull, 45, 134 - 140
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M. et al, (2021), Lancet Haematol, 8, e433 - e445
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
Crosswell HE. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)